Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Methods of Documentation II: POMR01:26

Methods of Documentation II: POMR

The Problem-Oriented Medical Record (POMR) revolutionized medical record-keeping by introducing a systematic approach focusing on the patient's problems rather than merely listing symptoms. Dr. Lawrence Weed's introduction of this method in the 1960s marked a significant advancement in medical documentation. The POMR framework consists of four key components: the database, problem list, plan of care, and progress notes.
Modified-Release Drug Delivery Systems: Overview01:19

Modified-Release Drug Delivery Systems: Overview

Modified-release dosage forms are designed to address the limitations of drugs with short biological half-lives. These forms maintain stable therapeutic drug concentrations over extended periods, reducing the need for frequent dosing. A consistent drug level helps minimize peak-trough fluctuations, which can reduce adverse effects, lower the risk of drug resistance, and improve overall treatment effectiveness.One common type of modified-release form is the extended-release (ER) formulation. ER...
Pharmacodynamic Models: Overview01:27

Pharmacodynamic Models: Overview

Pharmacodynamic (PD) responses describe the interaction between a drug and its biological target, culminating in a physiological effect. These responses can be classified into different types: continuous variables, such as blood glucose levels; categorical outcomes, like survival rates; and time-to-event metrics, such as disease progression. Understanding and modeling PD responses are critical for optimizing drug efficacy and safety.PD models describe the relationship between drug concentration...
Drug Administration and Therapy Phases: Overview01:26

Drug Administration and Therapy Phases: Overview

Drugs, the chemical agents used in diagnosing, treating, or preventing diseases, undergo a four-phase process of development: pharmaceutic, pharmacokinetics, pharmacodynamics, and therapeutic.
The pharmaceutical phase focuses on leveraging the physicochemical properties of the drug to design and manufacture an effective product. Variants include orally administered tablets or capsules, topical creams or ointments, and parenteral-delivery solutions or emulsions.
The pharmacokinetic phase...
Modified-Release Drug Delivery Systems: Classification01:23

Modified-Release Drug Delivery Systems: Classification

Modified-release drug delivery systems improve drug efficacy and minimize side effects by controlling the rate and location of drug release. These systems fall into three categories: rate-programmed, stimuli-activated, and site-targeted.Rate-programmed systems release drugs at a predetermined rate, maintaining consistent therapeutic levels and reducing fluctuations that could lead to toxicity or subtherapeutic effects. These systems use polymeric matrices, reservoir-based designs, or osmotic...
Preclinical Development: Overview01:28

Preclinical Development: Overview

Preclinical development consists of a series of tests that ensure the safety and efficacy of a new therapeutic compound before it is tested in humans. There are four main phases to this process. First, safety pharmacology tests are conducted to ensure the drug does not produce any acutely harmful effects. These tests examine parameters such as bronchoconstriction, cardiac dysrhythmias, blood pressure changes, and ataxia. Next, preliminary toxicological testing is performed to determine the...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Neuro-sensitization in cats with chronic pain and its association to osteoarthritis progression.

Frontiers in pain research (Lausanne, Switzerland)·2026
Same author

Evoked temporal summation in dogs to assess pain central sensitization and modulation - A feasibility study.

PloS one·2026
Same author

Somatosensory and visual evoked potentials and brainstem auditory evoked responses in osteoarthritic cats with chronic pain - a comparative study.

Frontiers in veterinary science·2026
Same author

EEG-based quantification of chronic pain in cats: A proof-of-concept study using the Piq algorithm.

Veterinary journal (London, England : 1997)·2026
Same author

An interpretable metabolomic-driven machine learning model for early prediction of knee structural OA progression.

Rheumatology (Oxford, England)·2025
Same author

Association between body weight fluctuation and progression of radiographic knee osteoarthritis: a longitudinal cohort study.

RMD open·2025

Related Experiment Video

Updated: Jul 11, 2026

In Vivo Functional Study of Disease-associated Rare Human Variants Using Drosophila
06:41

In Vivo Functional Study of Disease-associated Rare Human Variants Using Drosophila

Published on: August 20, 2019

DMOAD developments: present and future.

Jean-Pierre Pelletier1, Johanne Martel-Pelletier

  • 1Osteoarthritis Research Unit, University of Montreal Hospital Centre, Notre-Dame Hospital, Quebec, Canada. dr@jppelletier.ca

Bulletin of the NYU Hospital for Joint Diseases
|October 10, 2007
PubMed
Summary

Osteoarthritis (OA) research is advancing with new disease-modifying osteoarthritis drugs (DMOADs). Clinical trials show these drugs can slow structural damage in knee OA, offering hope for a cure.

Area of Science:

  • Rheumatology and Orthopedics
  • Pharmacology and Drug Discovery

Background:

  • Osteoarthritis (OA) is the most prevalent form of arthritis, posing a significant healthcare challenge.
  • Understanding OA's pathophysiology has identified key therapeutic targets for intervention.

Purpose of the Study:

  • To review the progress and potential of disease-modifying osteoarthritis drugs (DMOADs).
  • To highlight recent clinical trial findings demonstrating the efficacy of novel OA therapies.

Main Methods:

  • Review of current scientific literature and clinical trial data on OA treatments.
  • Analysis of newly discovered molecular targets and drug candidates for OA.

Main Results:

  • Several new classes of molecules targeting OA pathways are in clinical evaluation.

Related Experiment Videos

Last Updated: Jul 11, 2026

In Vivo Functional Study of Disease-associated Rare Human Variants Using Drosophila
06:41

In Vivo Functional Study of Disease-associated Rare Human Variants Using Drosophila

Published on: August 20, 2019

  • Recent clinical trials confirm that blocking key OA mechanisms can slow structural changes in knee OA.

    • Conclusions:

    • Emerging DMOADs represent a new era in OA treatment development.
    • These advancements offer the potential for disease modification and a future cure for osteoarthritis.